Shots:
- Protagonist to receive ~ $900M as development & sales milestones along with $80M already received under the original agreement with royalty rates remain unchanged. Janssen will get right to continue research on IL-23 receptor antagonists developed under a collaboration for 3yrs. following the closing of the amended agreement
- Janssen will lead all future studies beyond the currently ongoing studies with PTG-200, PN-232 and PN-235 and will be solely financially responsible for any studies. The company will deploy its capabilities & experience for further development of these assets
- PTG-200 is currently in P-II study for CD while PN-232 and PN-235 are currently in P-I clinical development
Click here to read full press release/ article | Ref: PR Newswire | Image: Protagonist
The post Janssen Amends its Agreement with Protagonist to Develop and Commercialize IL-23 Antagonists first appeared on PharmaShots.
